Pegylated Liposomal Doxorubicin Combinations for Platinum Resistant Ovarian Cancer

This clinical trial explores new treatment options for individuals with platinum-resistant ovarian cancer, a type of cancer that does not respond to standard platinum-based chemotherapy. The study aims to test the safety and effectiveness of different combinations of drugs, including pegylated liposomal doxorubicin, atezolizumab, and bevacizumab. These drugs are being tested to see if they can improve the length of time patients live without the cancer getting worse and to understand if they can extend overall survival. This research is important as it seeks to find more effective treatments for patients who have limited options due to their resistance to conventional therapy. Participants in this study are divided into three groups, each receiving different combinations of the drugs administered intravenously (through an IV). The treatments are given in cycles, with each cycle repeating every 28 days unless there is disease progression or unacceptable side effects. The study measures how long patients live without their cancer worsening and tracks overall survival rates. It also looks at the safety of the drug combinations and records any side effects experienced by patients. Throughout the trial, participants undergo regular CT scans to monitor their condition. After completing the treatment, patients are followed up periodically for up to five years to assess long-term outcomes.